Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia.

Stahl, MaximilianDeVeaux, MichelleMontesinos, PauItzykson, RaphaëlRitchie, Ellen KSekeres, Mikkael ABarnard, JohnPodoltsev, Nikolai ABrunner, AndrewKomrokji, Rami SBhatt, Vijaya RAl-Kali, ArefCluzeau, ThomasSantini, ValeriaRoboz, Gail JFenaux, PierreLitzow, MarkFathi, Amir TPerreault, SarahKim, Tae KonPrebet, ThomasVey, NorbertVerma, VivekGerming, UlrichBergua, JuanSerrano, JosefinaGore, Steven DZeidan, Amer M2023-01-252023-01-252018-07-02http://hdl.handle.net/10668/12666enAdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsDrug Resistance, NeoplasmFemaleHematopoietic Stem Cell TransplantationHumansLeukemia, Myeloid, AcuteMaleMiddle AgedNeoplasm Recurrence, LocalPrognosisRetrospective StudiesRisk AssessmentRisk FactorsSurvival AnalysisTransplantation, HomologousTreatment OutcomeYoung AdultPerformance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia.research article29963936open access10.1080/10428194.2018.14688931029-2403https://flore.unifi.it/bitstream/2158/1173639/2/stahl2018_MRC%20e%20LRF.pdf